The present invention relates to the use of mimotopes in the treatment of ß-Amyloidoses including but not limited to Alzheimers disease, whereby said mimotopes are able to induce the in vivo formation of antibodies directed to non truncated Aßl-40/42, and N-terminally truncated forms AßpE3-40/42, Aß3-40/42, Aß11-40/42, AßpEll-40/42 and Aß14-40/42 without interfering with physiological functions of APP signalling.